Clayton, Dubilier & Rice has closed an investment in PharMEDium Healthcare, a provider of hospital pharmacy compounding services. This transaction was first announced in December 2013.
PharMEDium’s sterile compounding services are used by hospitals to facilitate ready-to-use intravenous drug delivery to patients. Using FDA-approved drugs, diluents and containers, the company creates compounded sterile preparations (CSPs), which are not otherwise commercially available in the marketplace. PharMEDium provides CSPs in ready-to-use form with safety, labeling, stability, sterility and dating characteristics that are required by its hospital customers. PharMEDium serves more than 2,600 acute-care hospitals, academic medical centers, hospital groups, and standalone urban, suburban and rural hospitals. The company was founded by David Jonas in 2003 and is headquartered in the Chicago suburb of Lake Forest, IL (www.pharmedium.com).
Clayton, Dubilier & Rice focuses on producing financial returns through building stronger more profitable businesses. Since inception, the firm has managed the investment of more than $19 billion in 59 businesses representing a range of industries with an aggregate transaction value of approximately $90 billion. Founded in 1978, Clayton, Dubilier & Rice is based in New York and London (www.cdr-inc.com).
Clayton, Dubilier & Rice’s investment in PharMEDium Healthcare was first announced in December 2013 (Clayton, Dubilier & Rice Invests in PharMEDium).
© 2014 PEPD • Private Equity’s Leading News Magazine • 1-30-14
